Back to Search Start Over

A validated gene regulatory network and GWAS identifies early regulators of T cell–associated diseases

Authors :
Lars Alfredsson
Huan Zhang
Ingrid Kockum
Miguel Angel Pujana
Sandra Hellberg
Johan Mellergård
Jordi Serra-Musach
Robert Blomgran
Aelita Konstantinell
Subhash K. Tripathi
Melissa Mendez
Lina Mattson
Sergio E. Baranzini
Daniel Eklund
Riita Lahesmaa
Miro Viitala
Colm E. Nestor
H. Robert I. Liljenström
Tomas Olsson
Omid Rasool
Mika Gustafsson
Danuta R. Gawel
Antonio Lentini
Andreas Matussek
Margaretha Stenmarker
Jan Ernerudh
Hui Wang
Mikael Benson
Janne Björkander
Source :
Science Translational Medicine. 7
Publication Year :
2015
Publisher :
American Association for the Advancement of Science (AAAS), 2015.

Abstract

Early regulators of disease may increase understanding of disease mechanisms and serve as markers for presymptomatic diagnosis and treatment. However, early regulators are difficult to identify because patients generally present after they are symptomatic. We hypothesized that early regulators of T cell-associated diseases could be found by identifying upstream transcription factors (TFs) in T cell differentiation and by prioritizing hub TFs that were enriched for disease-associated polymorphisms. A gene regulatory network (GRN) was constructed by time series profiling of the transcriptomes and methylomes of human CD4(+) T cells during in vitro differentiation into four helper T cell lineages, in combination with sequence-based TF binding predictions. The TFs GATA3, MAF, and MYB were identified as early regulators and validated by ChIP-seq (chromatin immunoprecipitation sequencing) and small interfering RNA knockdowns. Differential mRNA expression of the TFs and their targets in T cell-associated diseases supports their clinical relevance. To directly test if the TFs were altered early in disease, T cells from patients with two T cell-mediated diseases, multiple sclerosis and seasonal allergic rhinitis, were analyzed. Strikingly, the TFs were differentially expressed during asymptomatic stages of both diseases, whereas their targets showed altered expression during symptomatic stages. This analytical strategy to identify early regulators of disease by combining GRNs with genome-wide association studies may be generally applicable for functional and clinical studies of early disease development. Funding Agencies|Cancer fund, Swedish Medical Research Council [K2013-61X-22310-01-04, 2012-3168]; Academy of Finland Centre of Excellence in Molecular Systems Immunology and Physiology Research [250114]; Sigrid Juselius Foundation; Generalitat de Catalunya AGAUR [2014-SGR364]; Spanish Association Against Cancer; Spanish Ministry of Health ISCIII FIS [PI12/01528]; RTICC [RD12/0036/0008]

Details

ISSN :
19466242 and 19466234
Volume :
7
Database :
OpenAIRE
Journal :
Science Translational Medicine
Accession number :
edsair.doi.dedup.....ec5eb927155d4646b060b6b130ef4a90
Full Text :
https://doi.org/10.1126/scitranslmed.aad2722